Jason Chia-Hsien Cheng

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3356612/publications.pdf

Version: 2024-02-01

121 papers	3,028 citations	159585 30 h-index	189892 50 g-index
128 all docs	128 docs citations	128 times ranked	3901 citing authors

#	Article	IF	Citations
1	Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1502-1509.	0.8	169
2	Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. International Journal of Radiation Oncology Biology Physics, 2002, 54, 156-162.	0.8	158
3	Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. International Journal of Radiation Oncology Biology Physics, 2000, 47, 435-442.	0.8	157
4	Comparison of intensity modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma. International Journal of Cancer, 2001, 96, 126-132.	5.1	121
5	Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description. Radiotherapy and Oncology, 2002, 63, 41-45.	0.6	102
6	A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 1999, 14, 1025-1033.	2.8	95
7	Radiation-Induced Hepatitis B Virus Reactivation in Liver Mediated by the Bystander Effect from Irradiated Endothelial Cells. Clinical Cancer Research, 2007, 13, 851-857.	7.0	94
8	Volumetric modulated arc therapy for nasopharyngeal carcinoma: A dosimetric comparison with TomoTherapy and step-and-shoot IMRT. Radiotherapy and Oncology, 2012, 104, 324-330.	0.6	93
9	Treatment and Dosimetric Advantages Between VMAT, IMRT, and Helical TomoTherapy in Prostate Cancer. Medical Dosimetry, 2011, 36, 264-271.	0.9	92
10	Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. Journal of the Formosan Medical Association, 2018, 117, 381-403.	1.7	92
11	Dosimetric analysis and comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy for patients with hepatocellular carcinoma and radiation-induced liver disease. International Journal of Radiation Oncology Biology Physics, 2003, 56, 229-234.	0.8	70
12	A Walk-and-Eat Intervention Improves Outcomes for Patients With Esophageal Cancer Undergoing Neoadjuvant Chemoradiotherapy. Oncologist, 2015, 20, 1216-1222.	3.7	63
13	Locoregional failure of postmastectomy patients with 1â€“3 positive axillary lymph nodes without adjuvant radiotherapy. International Journal of Radiation Oncology Biology Physics, 2002, 52, 980-988.	0.8	61
14	Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy. Acta Obstetricia Et Gynecologica Scandinavica, 2014, 93, 661-668.	2.8	57
15	Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization. International Journal of Cancer, 2001, 96, 243-252.	5.1	56
16	Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials. Liver Cancer, 2016, 5, 162-174.	7.7	53
17	MicroRNA-146a-5p Negatively Regulates Pro-Inflammatory Cytokine Secretion and Cell Activation in Lipopolysaccharide Stimulated Human Hepatic Stellate Cells through Inhibition of Toll-Like Receptor 4 Signaling Pathways. International Journal of Molecular Sciences, 2016, 17, 1076.	4.1	48
18	Inclusion of biological factors in parallel-architecture normal-tissue complication probability model for radiation-induced liver disease. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1150-1156.	0.8	46

#	Article	IF	Citations
19	Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting. Liver Cancer, 2017, 6, 264-274.	7.7	46
20	Radiation-Induced Interleukin-6 Expression Through MAPK/p38/NF-Î²B Signaling Pathway and the Resultant Antiapoptotic Effect on Endothelial Cells Through Mcl-1 Expression With sIL6-RÎ±. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1553-1561.	0.8	42
21	Retrospective Analysis of Outcome Differences in Preoperative Concurrent Chemoradiation With or Without Elective Nodal Irradiation for Esophageal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, e593-e599.	0.8	42
22	Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma. Oncotarget, 2014, 5, 3662-3672.	1.8	40
23	Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy. International Journal of Radiation Oncology Biology Physics, 2002, 53, 344-352.	0.8	38
24	Unique role of proximal rectal dose in late rectal complications for patients with cervical cancer undergoing high-dose-rate intracavitary brachytherapy. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1010-1018.	0.8	38
25	Comprehensive Locoregional Treatment and Systemic Therapy for Postmastectomy Isolated Locoregional Recurrence. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1456-1464.	0.8	38
26	Association of Clinical and Dosimetric Factors with Postoperative Pulmonary Complications in Esophageal Cancer Patients Receiving Intensity-Modulated Radiation Therapy and Concurrent Chemotherapy Followed by Thoracic Esophagectomy. Annals of Surgical Oncology, 2009, 16, 1669-1677.	1.5	35
27	Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinoma. Chronobiology International, 2016, 33, 210-219.	2.0	33
28	Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial. Neuro-Oncology, 2021, 23, 478-486.	1.2	33
29	Using Cone-Beam Computed Tomography to Evaluate the Impact of Bladder Filling Status on Target Position in Prostate Radiotherapy. Strahlentherapie Und Onkologie, 2009, 185, 588-595.	2.0	31
30	Radiation-induced VEGF-C expression and endothelial cell proliferation in lung cancer. Strahlentherapie Und Onkologie, 2014, 190, 1154-1162.	2.0	31
31	Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal. Practical Radiation Oncology, 2014, 4, 198-206.	2.1	31
32	Targeting histone deacetylase 4/ubiquitinâ€conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice. Hepatology, 2018, 67, 586-599.	7.3	29
33	Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. Radiotherapy and Oncology, 2018, 126, 368-374.	0.6	29
34	Improved local control by surgery and paclitaxelâ€based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective nonâ€randomized study. Journal of Surgical Oncology, 2008, 98, 34-41.	1.7	28
35	<scp>S</scp>onic <scp>H</scp>edgehog inhibition as a strategy to augment radiosensitivity of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1317-1324.	2.8	28
36	Unexpectedly frequent hepatitis B reactivation by chemoradiation in postgastrectomy patients. Cancer, 2004, 101, 2126-2133.	4.1	27

#	Article	IF	Citations
37	Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma. European Journal of Cancer, 2013, 49, 1458-1466.	2.8	27
38	Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells. Molecular Cancer Therapeutics, 2015, 14, 810-820.	4.1	26
39	Randomized multi-reader evaluation of automated detection and segmentation of brain tumors in stereotactic radiosurgery with deep neural networks. Neuro-Oncology, 2021, 23, 1560-1568.	1.2	26
40	Synergistic Effect of Radiation and Interleukin-6 on Hepatitis B Virus Reactivation in Liver Through STAT3 Signaling Pathway. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1545-1552.	0.8	25
41	Circulating mRNA Profiling in Esophageal Squamous Cell Carcinoma Identifies FAM84B As A Biomarker In Predicting Pathological Response to Neoadjuvant Chemoradiation. Scientific Reports, 2015, 5, 10291.	3.3	24
42	An evaluation of hepatocellular carcinoma practice guidelines from a radiation oncology perspective. Radiotherapy and Oncology, 2020, 148, 73-81.	0.6	23
43	Polymorphism in Epidermal Growth Factor Receptor Intron 1 Predicts Prognosis of Patients with Esophageal Cancer after Chemoradiation and Surgery. Annals of Surgical Oncology, 2011, 18, 2066-2073.	1.5	22
44	Radiosensitizing Effect of a Phenylbutyrate-Derived Histone Deacetylase Inhibitor in Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2012, 83, e181-e189.	0.8	22
45	Branched Î±-(1,4) Glucans from Lentinula edodes (L10) in Combination with Radiation Enhance Cytotoxic Effect on Human Lung Adenocarcinoma through the Toll-like Receptor 4 Mediated Induction of THP-1 Differentiation/Activation. Journal of Agricultural and Food Chemistry, 2011, 59, 11997-12005.	5.2	21
46	High Serum Levels of Vascular Endothelial Growth Factor-A and Transforming Growth Factor-Î²1 Before Neoadjuvant Chemoradiotherapy Predict Poor Outcomes in Patients with Esophageal Squamous Cell Carcinoma Receiving Combined Modality Therapy. Annals of Surgical Oncology, 2014, 21, 2361-2368.	1.5	21
47	Set-up errors due to endorectal balloon positioning in intensity modulated radiation therapy for prostate cancer. Radiotherapy and Oncology, 2007, 84, 177-184.	0.6	19
48	Mathematical estimation and in vivo dose measurement for cone-beam computed tomography on prostate cancer patients. Radiotherapy and Oncology, 2009, 92, 57-61.	0.6	19
49	Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption. International Journal of Cancer, 2014, 135, 492-501.	5.1	19
50	Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer, 2015, 4, 96-105.	7.7	19
51	Circular RNA TUBD1 Acts as the miR-146a-5p Sponge to Affect the Viability and Pro-Inflammatory Cytokine Production of LX-2 Cells through the TLR4 Pathway. Radiation Research, 2020, 193, 383.	1.5	19
52	Skin Dose Impact from Vacuum Immobilization Device and Carbon Fiber Couch in Intensity Modulated Radiation Therapy for Prostate Cancer. Medical Dosimetry, 2009, 34, 228-232.	0.9	18
53	MicroRNA-146a-5p Attenuates Fibrosis-related Molecules in Irradiated and TGF-beta1-Treated Human Hepatic Stellate Cells by Regulating PTPRA-SRC Signaling. Radiation Research, 2019, 192, 621.	1.5	18
54	Postoperative Intensity-Modulated Radiotherapy for Squamous Cell Carcinoma of the External Auditory Canal and Middle Ear: Treatment Outcomes, Marginal Misses, and Perspective on Target Delineation. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1485-1493.	0.8	17

#	Article	IF	Citations
55	Proteomic Profiling of Human Hepatic Stellate Cell Line LX2 Responses to Irradiation and TGF-Î²1. Journal of Proteome Research, 2019, 18, 508-521.	3.7	17
56	Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2015, 10, 1481-1489.	1.1	15
57	Outcome analysis of cervical adenosquamous carcinoma compared with adenocarcinoma. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 1158-1166.	2.8	14
58	Prone breast forward intensity-modulated radiotherapy for Asian women with early left breast cancer: factors for cardiac sparing and clinical outcomes. Journal of Radiation Research, 2013, 54, 899-908.	1.6	14
59	How to Improve Therapeutic Ratio in Radiotherapy of HCC. Liver Cancer, 2016, 5, 210-220.	7.7	14
60	Efforts to Reduce the Impact of Coronavirus Disease 2019 Outbreak on Radiation Oncology in Taiwan. Advances in Radiation Oncology, 2020, 5, 534-537.	1.2	14
61	A phase II study of early FDG-PET evaluation after one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy: Final report.. Journal of Clinical Oncology, 2017, 35, 4042-4042.	1.6	14
62	C1QTNF6 as a Novel Diagnostic and Prognostic Biomarker for Clear Cell Renal Cell Carcinoma. DNA and Cell Biology, 2020, 39, 1000-1011.	1.9	13
63	Should adjuvant radiotherapy to the supraclavicular fossa be routinely given in patients with breast conservative treatment?. Journal of Surgical Oncology, 2007, 96, 144-150.	1.7	12
64	Practically acquired and modified cone-beam computed tomography images for accurate dose calculation in head and neck cancer. Strahlentherapie Und Onkologie, 2011, 187, 633-644.	2.0	12
65	Comparison of tumor recurrence between laparoscopic total mesorectal excision with sphincter preservation and laparoscopic abdominoperineal resection for low rectal cancer. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 3452-3464.	2.4	12
66	Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma. Radiotherapy and Oncology, 2015, 115, 9-15.	0.6	12
67	The ratio of weight loss to planning target volume significantly impacts setup errors in nasopharyngeal cancer patients undergoing helical tomotherapy with daily megavoltage computed tomography. Radiology and Oncology, 2016, 50, 427-432.	1.7	12
68	Tumor-Derived C-C Motif Ligand 2 Induces the Recruitment and Polarization of Tumor-Associated Macrophages and Increases the Metastatic Potential of Bladder Cancer Cells in the Postirradiated Microenvironment. International Journal of Radiation Oncology Biology Physics, 2022, 114, 321-333.	0.8	12
69	Development and Validation of a Nomogram for Patients with Nonmetastatic BCLC Stage C Hepatocellular Carcinoma after Stereotactic Body Radiotherapy. Liver Cancer, 2020, 9, 326-337.	7.7	11
70	Circulating Exosomal Integrin Î²3 Is Associated with Intracranial Failure and Survival in Lung Cancer Patients Receiving Cranial Irradiation for Brain Metastases: A Prospective Observational Study. Cancers, 2021, 13, 380.	3.7	11
71	Biomarker Studies on Radiotherapy to Hepatocellular Carcinoma. Oncology, 2013, 84, 64-68.	1.9	10
72	Enhanced Radiosensitization for Cancer Treatment with Gold Nanoparticles through Sonoporation. International Journal of Molecular Sciences, 2020, 21, 8370.	4.1	10

#	Article	IF	Citations
73	Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival and Liver Toxicity in Patients With Hepatocellular Carcinoma Treated With Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 109, 474-484.	0.8	10
74	A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement. Journal of the Formosan Medical Association, 2017, 116, 689-696.	1.7	9
75	Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment. European Journal of Surgical Oncology, 2019, 45, 1498-1504.	1.0	9
76	Early Detection of Lewis Lung Carcinoma Tumor Control by Irradiation Using Diffusion-Weighted and Dynamic Contrast-Enhanced MRI. PLoS ONE, 2013, 8, e62762.	2.5	9
77	Treatment outcomes regarding the addition of targeted agents in the therapeutic portfolio for stage II-III rectal cancer undergoing neoadjuvant chemoradiation. Oncotarget, 2017, 8, 101832-101846.	1.8	9
78	Number of Resected Lymph Nodes and Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. Anticancer Research, 2018, 38, 1569-1577.	1.1	9
79	Radiosensitization in esophageal squamous cell carcinoma. Strahlentherapie Und Onkologie, 2016, 192, 260-268.	2.0	8
80	Lower postoperative natural killer cell activity is associated with positive surgical margins after radical prostatectomy. Journal of the Formosan Medical Association, 2020, 119, 1673-1683.	1.7	8
81	Superior liver sparing by combined coplanar/noncoplanar volumetric-modulated arc therapy for hepatocellular carcinoma: A planning and feasibility study. Medical Dosimetry, 2013, 38, 366-371.	0.9	7
82	Patterns of Nodal Metastases on 18F-FDG PET/CT in Patients With Esophageal Squamous Cell Carcinoma are Useful to Guide Treatment Planning of Radiotherapy. Clinical Nuclear Medicine, 2015, 40, 384-389.	1.3	7
83	Contactless Monitoring of Pulse Rate and Eye Movement for Uveal Melanoma Patients Undergoing Radiation Therapy. IEEE Transactions on Instrumentation and Measurement, 2019, 68, 474-482.	4.7	7
84	Preoperative Prognostic Neurologic Index for Glioblastoma Patients Receiving Tumor Resection. Annals of Surgical Oncology, 2014, 21, 3992-3998.	1.5	6
85	Targeting human epidermal growth factor receptor 2 enhances radiosensitivity and reduces the metastatic potential of Lewis lung carcinoma cells. Radiation Oncology, 2020, 15, 58.	2.7	6
86	Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. Journal of the Formosan Medical Association, 2019, 118, 1024-1030.	1.7	5
87	Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity. World Journal of Surgical Oncology, 2014, 12, 329.	1.9	4
88	The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer. World Journal of Surgical Oncology, 2015, 13, 312.	1.9	4
89	Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease?. Digestive Surgery, 2018, 35, 104-110.	1.2	4
90	Outcomes and Prediction Models for Exclusive Prostate Bed Salvage Radiotherapy among Patients with Biochemical Recurrence after Radical Prostatectomy. Cancers, 2021, 13, 2672.	3.7	4

#	Article	IF	Citations
91	Randomized Trials and New Directions inÂGastrointestinal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 91, 459-464.	0.8	3
92	Local Control and Clinical Outcome of High-risk Pediatric Neuroblastoma Patients After Receiving Multimodality Treatment and Helical Tomotherapy. Anticancer Research, 2019, 39, 2207-2215.	1.1	3
93	Risk Factors and Genetic Biomarkers of Multiple Primary Cancers in Esophageal Cancer Patients. Frontiers in Oncology, 2020, 10, 585621.	2.8	3
94	Multi-Institutional Retrospective Study of Radiotherapy for Hepatocellular Carcinoma in the Caudate Lobe. Frontiers in Oncology, 2021, 11, 646473.	2.8	3
95	Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation. Asian Journal of Andrology, 2017, 19, 596.	1.6	3
96	Evaluation of radiation dose and positioning accuracy on X-ray volume imaging system for image-guided radiotherapy. Nuclear Instruments & Methods in Physics Research B, 2008, 266, 2203-2206.	1.4	2
97	Essential Dosimetric Parameters of Liver for the Association With Radiation-Induced Liver Disease and Virus Reactivation: In Regard to Kim et al. (Int J Radiat Oncol Biol Phys 2007;69:813â€“819). International Journal of Radiation Oncology Biology Physics, 2008, 71, 961.	0.8	2
98	Radiation therapy for primary and metastatic tumors of the liver. Journal of Radiation Oncology, 2012, 1, 227-237.	0.7	2
99	Phase-specific cone beam computed tomography reduces reconstructed volume loss of moving phantom. Strahlentherapie Und Onkologie, 2012, 188, 77-83.	2.0	2
100	Pretreatment prostate specific antigen (PSA) and 2-year PSA dynamics: Early predictors of prostate cancer prognosis with external radiation therapy. Urological Science, 2013, 24, 120-123.	0.6	2
101	Serum Transforming Growth Factor-Î²1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1023-1031.	0.8	2
102	Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer. Case Reports in Oncology, 2016, 9, 474-480.	0.7	2
103	Impact of breath-hold level on positional error aligned by stent/Lipiodol in Hepatobiliary radiotherapy with breath-hold respiratory control. BMC Cancer, 2020, 20, 613.	2.6	2
104	CT-Based Collision Prediction Software for External-Beam Radiation Therapy. Frontiers in Oncology, 2021, 11, 617007.	2.8	2
105	A retrospective study of clinicopathologic and molecular features of inoperable early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy. Journal of the Formosan Medical Association, 2021, 120, 2176-2185.	1.7	2
106	Dual-timing PSA as a biomarker for patients with salvage intensity modulated radiation therapy for biochemical failure after radical prostatectomy. Oncotarget, 2016, 7, 44224-44235.	1.8	2
107	Longitudinal shear wave elasticity measurements of millimeter-sized biomaterials using a single-element transducer platform. PLoS ONE, 2022, 17, e0266235.	2.5	2
108	Gastrointestinal Cancersâ€”Changing the Standard forÂRectal Cancer and Establishing a New Standard forÂLiverÂTumors. International Journal of Radiation Oncology Biology Physics, 2016, 95, 930-936.	0.8	1

#	Article	IF	Citations
109	Peri-radiosurgical administration of bevacizumab improves radiographic response to single and fractionated stereotactic radiosurgery for large brain metastasis. Journal of Neuro-Oncology, 2021, 153, 455-465.	2.9	1
110	Competing Risk Analysis of Outcomes of Unresectable Pancreatic Cancer Patients Undergoing Definitive Radiotherapy. Frontiers in Oncology, 2021, 11, 730646.	2.8	1
111	Letters to the editor. International Journal of Radiation Oncology Biology Physics, 2000, 48, 909-910.	0.8	0
112	Different Dose escalation from plan normalization scheme. Radiotherapy and Oncology, 2000, 54, 284.	0.6	0
113	MODEL ANALYSIS OF RESPIRATION-RELATED DOSIMETRIC CHANGE DURING RADIOTHERAPY. Biomedical Engineering - Applications, Basis and Communications, 2002, 14, 35-39.	0.6	0
114	The chance of further chemoembolization and intrahepatic disease control after radiotherapy to portal vein thrombus. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1316.	0.8	0
115	Practical setup and appropriate parameters are essential for plan comparison: In regards to Ringash et al. (Int J Radiat Oncol Biol Phys 2005;63:732â€“738). International Journal of Radiation Oncology Biology Physics, 2006, 65, 311.	0.8	0
116	Programmable segmented volumetric modulated arc therapy for respiratory coordination in pancreatic cancer. Radiotherapy and Oncology, 2012, 104, 386-389.	0.6	0
117	Radiosensitization in Cancer Treatment with Gold nanoparticles through Synergistic Sonoporation. , 2019, , .		0
118	In Reply to Cousins et al. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1252-1253.	0.8	0
119	Using Megavoltage Computed Tomography to Estimate Radiotherapy Dose for High-Density Metallic Implants. IEEE Transactions on Instrumentation and Measurement, 2021, 70, 1-11.	4.7	0
120	SU-FF-T-222: The Analysis of Confounding Factors in Volume Reconstruction of 3DCRT with Spiral Mode CT Simulation. Medical Physics, 2005, 32, 2001-2001.	3.0	0
121	Evolving development of multi-parametric normal tissue complication probability model for liver radiotherapy. Translational Cancer Research, 2019, 8, S120-S123.	1.0	0